Jenburkt Pharmaceuticals reported a 24.45% year-on-year decline in standalone net profit after tax (PAT) for Q1FY27, dropping to ₹5.89 crore (₹588.56 lakhs). The contraction in profitability was driven by rising operational expenses, particularly in employee benefits, while revenue from operations remained virtually flat at ₹35.51 crore. The results were approved by the Board of Directors on August 6, 2026, and published in newspapers on August 7, 2026.

The Board of Directors approved the unaudited financial results following a review by the Audit Committee. The results were prepared in accordance with Ind AS 34 and reviewed by statutory auditors D.R. Mehta & Associates under Regulation 33 read with Regulation 47(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The limited review report confirmed no material misstatements. Ashish U. Bhuta, Chairman & Managing Director, signed off on the results, which were subsequently published in The Free Press Journal (English) and Navshakti (Marathi) on August 7, 2026.

Financial Performance

Revenue from operations stood at ₹3,551.20 lakhs, marginally down from ₹3,552.68 lakhs in Q1FY26. Total income reached ₹3,702.52 lakhs, including other income of ₹151.32 lakhs. This represents a significant drop in other income from ₹434.83 lakhs in Q4FY26. Profit before tax fell to ₹676.91 lakhs from ₹1,018.20 lakhs in the same period last year. Basic and diluted earnings per share (EPS) decreased to ₹13.34 from ₹17.66 in Q1FY26.

What the Numbers Show

The primary driver behind the profit decline was a surge in employee benefit expenses, which rose to ₹1,302.52 lakhs in Q1FY27 from ₹1,172.08 lakhs in Q1FY26. This increase outpaced the negligible growth in revenue, squeezing operating margins. Additionally, other expenses climbed to ₹1,013.81 lakhs from ₹833.11 lakhs year-on-year. While cost of materials consumed decreased slightly to ₹231.59 lakhs, the overall expense burden increased relative to income generation. The absence of exceptional items in Q1FY27 contrasts with Q4FY26, where a one-time gain of ₹395.11 lakhs related to Labour Code impacts had boosted profits.

Jenburkt Pharmaceuticals has scheduled its 41st Annual General Meeting (AGM) for September 4, 2026, at 3:30 p.m. IST. The meeting will be conducted via Video Conferencing (VC) or Other Audio Visual Means (OAVM) in compliance with the Companies Act, 2013, and the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI-LODR). Shareholders holding shares as of the August 28, 2026 cut-off date are eligible to vote on all resolutions presented in the notice.

The company dispatched the notice convening the AGM, along with the Annual Report for the financial year 2025-26 (FY25-26), to members via electronic mode on August 3, 2026. This dispatch was made in accordance with Rule 20(4) of the Companies (Management and Administration) Rules, 2014, and Ministry of Corporate Affairs General Circular No. 03/2025 dated September 22, 2025. Newspaper advertisements confirming the meeting were published in The Free Press Journal (English) and Navshakti (Marathi) on August 4, 2026.

E-Voting Schedule and Eligibility

Members can cast their votes using the remote e-voting facility provided by National Securities Depository Limited (NSDL). The voting window is open for three days prior to the AGM. Voting rights are proportional to the paid-up value of equity shares held as of the cut-off date.

Once a vote is cast via remote e-voting, it cannot be changed. Members who have already voted remotely may attend the AGM via VC/OAVM but cannot vote again. Those attending the meeting who have not voted remotely may exercise their voting rights during the AGM or within 15 minutes after its conclusion.

Regulatory Compliance and Member Instructions

The company complied with Regulation 36(1)(b) of SEBI-LODR by sending letters containing web-links to the complete Annual Report details to members who have not registered their email addresses with the company, Registrar to an Issue & Share Transfer Agent (RTA), or Depository Participants (DPs). The full notice and annual report are available on the company’s website at www.jenburkt.com and the BSE Limited website at www.bseindia.com .

Members are advised to update their PAN, contact details, bank account information, specimen signatures, and nomination details with their DPs if shares are held in demat form. Physical shareholders must submit duly filled Forms ISR-1 and ISR-2 to the company or RTA. Service requests can also be submitted online via the RTA’s ‘iConnect’ portal. For queries regarding login IDs or e-voting, members may contact NSDL’s Assistant Vice President, Veena Suvarna, or refer to the FAQs on www.evoting.nsdl.com .